Vaccination of patients with stage IV melanoma with dendritic cells generated ex vivo from monocytes and loaded with heat treated killed allogeneic melanoma cells.

Trial Profile

Vaccination of patients with stage IV melanoma with dendritic cells generated ex vivo from monocytes and loaded with heat treated killed allogeneic melanoma cells.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs ODC 0501 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Baylor Research Institute
  • Most Recent Events

    • 02 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top